These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1857840)

  • 1. [Heparin anticoagulant activity: new knowledge and future prospects].
    Camici M; Giusti C; Evangelisti L
    Recenti Prog Med; 1991 Apr; 82(4):209-18. PubMed ID: 1857840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
    Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA
    Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular weight of heparin versus biologic activity. Some additional considerations.
    Losito R; Losito C
    Semin Thromb Hemost; 1985 Jan; 11(1):29-33. PubMed ID: 2579437
    [No Abstract]   [Full Text] [Related]  

  • 5. [From heparin to heparins: toward new therapeutic perspectives?].
    Molho P; Tobelem G
    Biomed Pharmacother; 1987; 41(4):171-5. PubMed ID: 3620582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The characteristics of anticoagulation by covalently immobilized heparin.
    Miura Y; Aoyagi S; Kusada Y; Miyamoto K
    J Biomed Mater Res; 1980 Sep; 14(5):619-30. PubMed ID: 7349668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacology of heparin].
    Hoffmann A; Markwardt F
    Z Gesamte Inn Med; 1979 Jan; 34(1):3-8. PubMed ID: 373277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard and method independent units for heparin anticoagulant activities.
    Hemker HC; Béguin S
    Thromb Haemost; 1993 Nov; 70(5):724-8. PubMed ID: 8128425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Low molecular weight heparins].
    Kher A; Bara L; Samama M
    Pathol Biol (Paris); 1986 Jan; 34(1):61-9. PubMed ID: 3517772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
    Rezaie AR
    Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New antithrombin-based anticoagulants.
    Desai UR
    Med Res Rev; 2004 Mar; 24(2):151-81. PubMed ID: 14705167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic heparin derivatives as new anticoagulant drugs.
    de Kort M; Buijsman RC; van Boeckel CA
    Drug Discov Today; 2005 Jun; 10(11):769-79. PubMed ID: 15922935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible mechanism of the synergistic effect of heparin and dihydroergotamine.
    Kakkar VV; Welzel D; Murray WJ; Malone P; Jones D
    Am J Surg; 1985 Oct; 150(4A):33-8. PubMed ID: 4051120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulant property of a semi-synthesized sodium beta-1,4-glucan sulfate.
    Wang ZM; Li L; Li B; Guo SY
    Yao Xue Xue Bao; 2006 Apr; 41(4):323-7. PubMed ID: 16856476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.